ARIEL3

Analysts at Leerink maintain an Outperform rating on shares ofClovis Oncology Inc (NASDAQ: CLVS) with a price target boosted from $85 to $114 after the company hosted a conference call on Monday, which addressed some of the biggest controversies it faces. Clovis' conference calls came after the...

Shares of Clovis Oncology Inc (NASDAQ: CLVS), a biopharmaceutical company that develops an ovarian cancer drug called Rubraca (rucaparib), surged higher by 45 percent early Monday morning after the company released encouraging late-stage data from an ongoing trial called ARIEL3. Clovis' ARIEL3 is a...